期刊文献+

TgAb阳性时分化型甲状腺癌患者荷瘤状况分析及阳性TgAb对Tg临床价值的影响 被引量:2

Analysis of the status of loading metastatic lesions in DTC with positive TgAb and the effect of positive TgAb on the clinical value of Tg
原文传递
导出
摘要 目的分析甲状腺球蛋白抗体(TgAb)阳性时分化型甲状腺癌(DTC)患者荷瘤状况,间接评价阳性TgAb对甲状腺球蛋白(Tg)临床价值的影响。方法收集52例共69例次TgAb阳性DTC患者,对其131I治疗后的扫描结果进行分析,结合X线、CT、MRI、B超及临床随访等资料进行综合判断患者转移病灶的状况。有转移灶者为阳性。结果 Tg≥10μg/L、10~2.0μg/L、2~0.1μg/L、≤0.1μg/L 4组转移灶阳性率分别为80.95%、53.84%、58.82%、50.00%。组间差异无统计学意义(P〉0.05)。结论 TgAb阳性时,转移灶阳性率与Tg水平无相关性,阳性TgAb削弱了Tg的临床价值。 Objective To analyse the status of loading metastatic lesions in patients with differentiated thyroid cancer(DTC) with positive antithyroglobulin(P-TgAb) and evaluate the effect of P-TgAb on the clinical value of thyroglobulin(Tg) indirectly.Methods Data of 52 DTC patients with P-TgAb including 69 131I treatments were analyzed,which included scintigraphy after every 131I treatment X-ray,CT,MRI,B-type ultrasonography and follow-up.The positive rate of metastatic lesions was calculated.Results The positive rates of four groups of Tg≥10 μg/L,10~2.0 μg/L,2~0.1 μg/L and ≤0.1 μg/L were 80.95%,53.84%,58.82% and 50.00%,respectively(P0.05).Conclusion When TgAb is positive,the positive rate of metastatic lesions is not correlated to the level of Tg.The P-TgAb reduces the clinical value of Tg.
出处 《江苏医药》 CAS CSCD 北大核心 2011年第7期829-831,共3页 Jiangsu Medical Journal
关键词 分化型甲状腺癌 荷瘤 阳性甲状腺球蛋白抗体 甲状腺球蛋白 Differentiated thyroid cancer Loading metastatic lesion Positive antithyroglobulin Thyroglobulin
  • 相关文献

参考文献6

二级参考文献48

  • 1范西红,张小桥.分化性甲状腺癌手术治疗的研究进展[J].实用医药杂志,2004,21(7):657-660. 被引量:3
  • 2嵇庆海,王玉龙,郭智.甲状腺癌诊治进展[J].肿瘤研究与临床,2006,18(3):214-216. 被引量:27
  • 3朱瑞森,余永利,陆汉魁,罗全勇,陈立波.分化型甲状腺癌术后^(131)I治疗的必要性[J].上海交通大学学报(医学版),2006,26(9):1042-1043. 被引量:20
  • 4Whitley R J, Ain K B. Thyroglobulin : a specific serum marker for the management of thyroid carcinoma [ J ]. Clin Lab Med, 2004, 2,4( 1 ) : 29-47.
  • 5Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for lhe diagnosis and monitoring of thyroid disease [J]. Thyroid, 2003, 13( 1 ) :123-126.
  • 6Iervasi A, Iervasi G, Carpi A, et al. Serum thyroglobulin measurement: clinical background and main methodological aspects with clinical impact[ J ]. Biomed Pharmacother, 2006, 60 ( 8 ) : 414- 424.
  • 7Cobin R H, Gharib H, Bergman D A, et al. AACE/AAES medical/surgical guidelines for clinical practice : management of lhyroid carcinoma [ J]. Endocrine Pract, 2001, 7 (3) :202-220.
  • 8Torrens J I, Burch H B. Serum thyroglobulin measurement. Utility in clinical practice [J]. Endocrinol Metab Clin North Am, 2001, 30(2) : 429-467.
  • 9Bugalho M J, Domingues R S, Pinto A C, et al. Detection of thyroglobulin mRNA transcripts in peripheral blood of individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells [J]. Eur J Endocrinol, 2001, 145(4) :409-413.
  • 10Elisei R, Vivaldi A, Agate L, et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients [ J]. J Clin Endocrinol Metab, 2004, 89 ( 1 ) : 33-39.

共引文献27

同被引文献23

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部